AN2 Therapeutics ANTX 深 沪
已收盘 10-10 16:00:00 美东时间
1.26
+0.020
+1.61%
华盛通- 最 高1.31
- 今 开1.25
- 成交量 8.25万股
- 最 低 1.25
- 昨 收 1.24
- 总市值 3443.10万
- 52周最高 1.675
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 0.975
- 委 比 69.89%
- 总股本 2732.62万
- 历史最高 23.58
- 量 比 1.58
- 振 幅 4.84%
- 历史最低 0.87
- 每 手 1
- 风险率 0.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anterix Announces Executive Leadership Changes to Power Next Phase of Growth
<p>Anterix announced changes in its executive leadership team to enhance its ability to deliver advanced connectivity solutions for critical industries. Heather Martin has been appointed as Chief Marketing Officer and Chief of Staff, bringing over 20 years of global marketing experience. Elena Marquez succeeds Tim Gray as Chief Financial Officer, with a strong background in financial leadership. These appointments aim to strengthen Anterix’s mark...
09-18 11:30
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders from September 4 to September 11, 2025, to allow more time for shareholder voting. The meeting will now be held virtually. Voting details and deadlines have been updated to accommodate the new date. The Company's Board recommends stockholders vote FOR the proposals outlined in the Proxy Statement filed with the SEC on August 18, 2025. The Proxy Statement and relat...
09-04 05:42
AN2 Therapeutics Q2 EPS $(0.21) Beats $(0.30) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.30) by 30.69 percent. This is a 56.25 percent increase over losses of $(0.48) per share from
08-13 04:20
Anterix Sets First Quarter Fiscal 2026 Earnings Conference Call for Wednesday, August 13, at 9:00 a.m. ET
<p>Anterix (NASDAQ: ATEX) announced it will host a conference call on August 13, 2025, at 9:00 a.m. ET to discuss its first quarter fiscal 2026 results. A press release will be issued on August 12, 2025. Interested participants must pre-register to join the live Q&A session. The call will be webcast live and available on Anterix’s Investor Relations website. A replay will be posted afterward. Anterix specializes in 900 MHz broadband solutions for...
07-22 15:30
AN2 Therapeutics Completed Its 200-patient Observational Study In Acute Melioidosis. The Study Evaluated Patients Receiving The Current Standard Of Care: IV Meropenem Or Ceftazidime
Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraboroleObservational Study funded by the National Institutes of Health
06-30 19:11
AN2 Therapeutics Unveils Updated Investor Presentation
AN2 Therapeutics, Inc. ( ($ANTX) ) just unveiled an announcement. On June 11, 2...
06-11 19:59
AN2 Therapeutics Elects New Directors at Annual Meeting
AN2 Therapeutics, Inc. ( ($ANTX) ) has shared an announcement. On May 22, 2025,...
05-28 05:09
AN2 Therapeutics Q1 GAAP EPS $(0.35) Misses $(0.26) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.26) by 34.62 percent. This is a 37.5 percent increase over losses of $(0.56) per share from
05-14 06:01
快讯 | AN2 Therapeutics Inc：预计现金流将资助运营至2028年
AN2 Therapeutics Inc: Cash Runway Anticipated to Fund Operations Into 2028
05-14 04:02
快讯 | AN2 Therapeutics报告2025财年第一季度财务业绩以及近期的业务和科学亮点
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Busine...
05-14 04:01
